JP2000507263A - 7―アミノ―2―ヘプテノエートおよびメチルフェニデートの製造におけるその使用 - Google Patents
7―アミノ―2―ヘプテノエートおよびメチルフェニデートの製造におけるその使用Info
- Publication number
- JP2000507263A JP2000507263A JP9534133A JP53413397A JP2000507263A JP 2000507263 A JP2000507263 A JP 2000507263A JP 9534133 A JP9534133 A JP 9534133A JP 53413397 A JP53413397 A JP 53413397A JP 2000507263 A JP2000507263 A JP 2000507263A
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- cooch
- blocking group
- methylphenidate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 title claims abstract description 7
- 229960001344 methylphenidate Drugs 0.000 title claims abstract description 5
- MEQZLBSYGZAXND-UHFFFAOYSA-N 7-aminohept-2-enoic acid Chemical compound NCCCCC=CC(O)=O MEQZLBSYGZAXND-UHFFFAOYSA-N 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 230000000903 blocking effect Effects 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- NCFSDGWPAKOPOU-UHFFFAOYSA-N n-ethylethanamine;lithium Chemical group [Li].CCNCC NCFSDGWPAKOPOU-UHFFFAOYSA-N 0.000 claims description 2
- 238000006957 Michael reaction Methods 0.000 claims 1
- 238000006845 Michael addition reaction Methods 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- 238000007363 ring formation reaction Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- -1 t-butyloxycarbonyl Chemical group 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- BEHBHYYPTOHUHX-UHFFFAOYSA-N (2-bromophenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1Br BEHBHYYPTOHUHX-UHFFFAOYSA-N 0.000 description 1
- CLWAXFZCVYJLLM-UHFFFAOYSA-N 1-chlorohexadecane Chemical compound CCCCCCCCCCCCCCCCCl CLWAXFZCVYJLLM-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical group CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LQGKDMHENBFVRC-UHFFFAOYSA-N 5-aminopentan-1-ol Chemical compound NCCCCCO LQGKDMHENBFVRC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical class [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 description 1
- 229960001042 dexmethylphenidate Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- DUGOZIWVEXMGBE-OLZOCXBDSA-N methyl (S)-phenyl[(R)-piperidin-2-yl]acetate Chemical compound C([C@@H]1[C@@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-OLZOCXBDSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 125000005543 phthalimide group Chemical group 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.次式: Y1Y2N−(CH2)4−CH=C(Ph)−X (式中、Y1とY2は相互に独立してHもしくは脱離可能なブロッキング基を示 すか、またはY1とY2は一体となって脱離可能な二価のブロッキング基を示し、 XはCOOCH3またはこれに変換可能な基を示す) で表される化合物。 2.XがCN、CONH2またはCOOR1であり、R1がHまたは炭素原子数 が10までのアルキルもしくはアラルキルである請求項1記載の化合物。 3.Y1がHまたはキラル補助基である請求項1記載の化合物。 4.Y1が1−フェニルエチルである請求項1から3いずれかに記載の化合物 。 5.Y2がHである請求項3または4記載の化合物。 6.次式: Ph−CHX−PO(O−alk)2 および Y1Y2N−(CH2)4−CHO (式中、Y2はブロッキング基を示す) で表される対応する化合物のホルナー-ワーズウォース-エモンス反応をおこない 、次いで、所望によりブロッキング基を脱離させることによってY2がHである 生成物を得ることを含む請求項1から5いずれかに記載の化合物の製造方法。 7.請求項5記載の化合物を塩基を用いてマイケル反応させ、次いでブロッキ ング基Y1を脱離させ、次いでXがCOOCH3でないときにはXをCOOCH3 に変換させることを含むメチルフェニデートの製造方法。 8.塩基がリチウムジエチルアミンである請求項7記載の方法。 9.Y1が1−フェニルエチルであって、該基が水素化によって脱離される請 求項7または8記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9606417.5A GB9606417D0 (en) | 1996-03-27 | 1996-03-27 | Asymmetric cyclisation |
GB9606417.5 | 1996-03-27 | ||
PCT/GB1997/000811 WO1997035836A1 (en) | 1996-03-27 | 1997-03-21 | 7-amino-2-heptenoates and their use in the preparation of methylphenidate |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000507263A true JP2000507263A (ja) | 2000-06-13 |
Family
ID=10791096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9534133A Pending JP2000507263A (ja) | 1996-03-27 | 1997-03-21 | 7―アミノ―2―ヘプテノエートおよびメチルフェニデートの製造におけるその使用 |
Country Status (14)
Country | Link |
---|---|
US (1) | US6031124A (ja) |
EP (1) | EP0889874B1 (ja) |
JP (1) | JP2000507263A (ja) |
KR (1) | KR100472753B1 (ja) |
AT (1) | ATE212616T1 (ja) |
AU (1) | AU703927B2 (ja) |
CA (1) | CA2243544C (ja) |
DE (1) | DE69710181T2 (ja) |
DK (1) | DK0889874T3 (ja) |
ES (1) | ES2172767T3 (ja) |
GB (1) | GB9606417D0 (ja) |
MX (1) | MX202731B (ja) |
PT (1) | PT889874E (ja) |
WO (1) | WO1997035836A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US6486177B2 (en) | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US5859249A (en) * | 1997-02-19 | 1999-01-12 | Takasago International Corporation | 2-phenyl-2-(2'-piperidinylidene)acetate derivative, process for manufacturing the same, and process for manufacturing optically active 2-phenyl-2-(2'-piperidinyl)acetate derivative by asymmetrically hydrogenating the same |
EP0860426A1 (en) * | 1997-02-19 | 1998-08-26 | Takasago International Corporation | 7-(n-substituted amino)-2-phenylheptanoic acid derivative and process for manufacturing the same |
US6962997B1 (en) * | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
US6100401A (en) * | 1998-04-20 | 2000-08-08 | Novartris Ag | Process for preparing the d-threo isomer of methylphenidate hydrochloride |
US6025502A (en) * | 1999-03-19 | 2000-02-15 | The Trustees Of The University Of Pennsylvania | Enantopselective synthesis of methyl phenidate |
US20050239830A1 (en) * | 2004-04-26 | 2005-10-27 | Vikram Khetani | Methods of diminishing co-abuse potential |
CN101076248A (zh) * | 2004-12-09 | 2007-11-21 | 塞尔基因公司 | 使用d-苏型哌甲酯的治疗 |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
WO2012129551A1 (en) | 2011-03-23 | 2012-09-27 | Ironshore Pharmaceuticals & Development, Inc. | Methods and compositions for treatment of attention deficit disorder |
US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2957880A (en) * | 1953-12-23 | 1960-10-25 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
JPS537627A (en) * | 1976-07-07 | 1978-01-24 | Teijin Ltd | Optically active unsaturated esters and their preparation |
-
1996
- 1996-03-27 GB GBGB9606417.5A patent/GB9606417D0/en active Pending
-
1997
- 1997-03-21 US US09/155,322 patent/US6031124A/en not_active Expired - Fee Related
- 1997-03-21 PT PT97908413T patent/PT889874E/pt unknown
- 1997-03-21 JP JP9534133A patent/JP2000507263A/ja active Pending
- 1997-03-21 AT AT97908413T patent/ATE212616T1/de not_active IP Right Cessation
- 1997-03-21 DE DE69710181T patent/DE69710181T2/de not_active Expired - Fee Related
- 1997-03-21 CA CA002243544A patent/CA2243544C/en not_active Expired - Fee Related
- 1997-03-21 AU AU20386/97A patent/AU703927B2/en not_active Ceased
- 1997-03-21 EP EP97908413A patent/EP0889874B1/en not_active Expired - Lifetime
- 1997-03-21 ES ES97908413T patent/ES2172767T3/es not_active Expired - Lifetime
- 1997-03-21 KR KR10-1998-0707378A patent/KR100472753B1/ko not_active IP Right Cessation
- 1997-03-21 DK DK97908413T patent/DK0889874T3/da active
- 1997-03-21 WO PCT/GB1997/000811 patent/WO1997035836A1/en active IP Right Grant
-
1998
- 1998-09-25 MX MX9807879A patent/MX202731B/es not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2172767T3 (es) | 2002-10-01 |
CA2243544A1 (en) | 1997-10-02 |
MX9807879A (en) | 1999-02-28 |
PT889874E (pt) | 2002-06-28 |
US6031124A (en) | 2000-02-29 |
DE69710181D1 (de) | 2002-03-14 |
DE69710181T2 (de) | 2002-08-14 |
EP0889874B1 (en) | 2002-01-30 |
MX202731B (en) | 2001-06-29 |
KR100472753B1 (ko) | 2005-07-07 |
ATE212616T1 (de) | 2002-02-15 |
WO1997035836A1 (en) | 1997-10-02 |
DK0889874T3 (da) | 2002-05-06 |
AU2038697A (en) | 1997-10-17 |
EP0889874A1 (en) | 1999-01-13 |
AU703927B2 (en) | 1999-04-01 |
CA2243544C (en) | 2002-11-19 |
GB9606417D0 (en) | 1996-06-05 |
KR19990087826A (ko) | 1999-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000507263A (ja) | 7―アミノ―2―ヘプテノエートおよびメチルフェニデートの製造におけるその使用 | |
KR100549748B1 (ko) | 프레가발린의 비대칭 합성 | |
EP0724563B1 (en) | Intermediates for the preparation of a substituted 2,5-diamino-3-hydroxyhexane. | |
US20030225149A1 (en) | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | |
CZ296895B6 (cs) | Zpusob prípravy kyseliny (+-)-3-(aminomethyl)-5-methylhexanové | |
MXPA98007879A (en) | 7-amino-2-heptenoatos and its use in the preparation of metilfenid | |
JP2001504125A (ja) | シクロプロピルアミンの製造法 | |
US6346618B1 (en) | Optical resolution of narwedine-type compounds | |
JP3478827B2 (ja) | アミド誘導体 | |
Enders et al. | Asymmetric Synthesis of α‐Substituted N‐Methylsulfonamides | |
KR20010042750A (ko) | 거울상 이성질체-유리n-메틸-n-[(1s)-1-페닐-2-((3s)-3-히드록시피롤리딘-1-일)에틸]-2,2-디페닐아세트아미드의 제조 방법 | |
JP2001521498A (ja) | O−(3−アミノ−2−ヒドロキシ−プロピル)−ヒドロキシミック酸ハロゲン化物の製造方法 | |
US8058456B2 (en) | Optically active 3-amino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the compound, and use of the compound | |
JP2000504684A (ja) | 第4級キラル中心のラセミ化 | |
JPH1121275A (ja) | アミノニトリル誘導体の製造方法 | |
Ruano et al. | Synthesis of enantiomerically pure acyclic α-sulfinyl ketimines | |
JP2003500333A (ja) | 4−[(2’,5’−ジアミノ−6’−ハロゲンピリミジン−4’−イル)アミノ]シクロペント−2−エンイルメタノールの製造方法 | |
CA2256380C (en) | Optical resolution of narwedine-type compounds | |
JP4267125B2 (ja) | ピリジンアルコール誘導体の製造方法 | |
JP4236311B2 (ja) | シクロヘプトイミダゾール誘導体の製造方法 | |
Hicks et al. | Synthesis of 13C and 14C labeled pirmenol hydrochloride | |
WO2000053575A1 (fr) | SYNTHESE DE α-AMINO-α',α'-DIHALOCETONES ET PROCEDE DE PREPARATION DE DERIVES D'ACIDES AMINES β PAR UTILISATION DE CES DERNIERS | |
AU9238598A (en) | Improved methods of preparing 4-cyano-4-(substituted indazole)cyclohexane-carboxylic acids useful as PDE4 inhibitors | |
JP2002530398A (ja) | 3環式化合物のエナンチオ選択的アルキル化 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040108 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061024 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070124 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070320 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20070618 |